Cargando…

Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV

To evaluate safety and immunogenicity of V114 [15-valent pneumococcal conjugate vaccine (PCV) containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F], followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) 8 weeks later, in adults living with HIV. DESIGN: I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohapi, Lerato, Pinedo, Yvett, Osiyemi, Olayemi, Supparatpinyo, Khuanchai, Ratanasuwan, Winai, Molina, Jean-Michel, Dagan, Ron, Tamms, Gretchen, Sterling, Tina, Zhang, Ying, Pedley, Alison, Hartzel, Jon, Kan, Yanqing, Hurtado, Kim, Musey, Luwy, Simon, Jakub K., Buchwald, Ulrike K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815827/ https://www.ncbi.nlm.nih.gov/pubmed/34750291 http://dx.doi.org/10.1097/QAD.0000000000003126

Ejemplares similares

Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU)
por: Severance, Randall, et al.
Publicado: (2021)

Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18–49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY)
por: Hammitt, Laura L, et al.
Publicado: (2021)

Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors
por: Hammitt, Laura L., et al.
Publicado: (2023)

Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study
por: Quinn, Charles T., et al.
Publicado: (2022)

1050. Phase 3 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by 23valent Pneumococcal Polysaccharide Vaccine 6 Months Later in At-risk Adults Aged 18–49 Years (PNEU-DAY): A Subgroup Analysis by Baseline Risk Factors
por: Hammitt, Laura, et al.
Publicado: (2021)

1972. Safety and Immunogenicity of 15-Valent Pneumococcal Conjugate Vaccine (PCV-15) Compared with PCV-13 in Healthy Older Adults Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23)
por: Buchwald, Ulrike, et al.
Publicado: (2018)

A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM)
por: Wilck, Marissa, et al.
Publicado: (2023)

P06 The 15-valent pneumococcal conjugate vaccine (PCV) V114 induces cross-reactive antibodies against pneumococcal serotype 6C
por: Shi, Yaru, et al.
Publicado: (2023)

The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C
por: Shi, Yaru, et al.
Publicado: (2023)

Safety and Immunogenicity of V114 in Preterm Infants: A Pooled Analysis of Four Phase Three Studies
por: Chapman, Timothy J., et al.
Publicado: (2023)

1174. Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Catch-up Vaccination Regimens of V114 in Healthy Infants, Children, and Adolescents (PNEU–PLAN)
por: Banniettis, Natalie, et al.
Publicado: (2021)

A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV
por: Wilck, Marissa, et al.
Publicado: (2023)

P08 A Phase 1, randomized, double-blind study to evaluate the safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine (PCV) (V116) in adults
por: Platt, Heather, et al.
Publicado: (2023)

A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
por: Platt, Heather L., et al.
Publicado: (2020)

P07 A Phase 3 randomized, double-blind, comparator-controlled study to evaluate safety, tolerability and immunogenicity of V114 pneumococcal vaccine in haematopoietic cell transplant recipients (PNEU-STEM)
por: Wilck, Marissa, et al.
Publicado: (2023)

Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older
por: Buchwald, Ulrike K., et al.
Publicado: (2021)

Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly
por: Kawakami, Kenji, et al.
Publicado: (2018)

P1576: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF V114 PNEUMOCOCCAL VACCINE IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS (PNEU-STEM)
por: Wilck, M., et al.
Publicado: (2022)

Evaluation of a 15-valent Pneumococcal Conjugate Vaccine in an Adult Rhesus Macaque Immunogenicity Model
por: Xie, Jinfu, et al.
Publicado: (2017)

1184. A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)
por: Bili, Adroniki, et al.
Publicado: (2021)

Phase 1 Clinical Trial of a Replication-Defective Human Cytomegalovirus (CMV) Vaccine
por: Adler, Stuart, et al.
Publicado: (2017)

Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand: a retrospective study
por: Kawila, Rathakarn, et al.
Publicado: (2013)

Appropriate Time to Start Antiretroviral Therapy in HIV-infected Patients with Penicilliosis marneffei
por: Utkham, Thongchai, et al.
Publicado: (2017)

Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study
por: Steens, Jean-Marc, et al.
Publicado: (2017)

Incidence and risk factors of antiretroviral treatment failure in treatment-naïve HIV-infected patients at Chiang Mai University Hospital, Thailand
por: Khienprasit, Nitta, et al.
Publicado: (2011)

Autoantibody to Interferon-gamma Associated with Adult-Onset Immunodeficiency in Non-HIV Individuals in Northern Thailand
por: Wongkulab, Panuwat, et al.
Publicado: (2013)

Comparison of Immunogenicity and Safety of Four Doses and Four Double Doses vs. Standard Doses of Hepatitis B Vaccination in HIV-Infected Adults: A Randomized, Controlled Trial
por: Chaiklang, Kanokporn, et al.
Publicado: (2013)

Cellular Immune Responses in HIV-Negative Immunodeficiency with Anti-Interferon-γ Antibodies and Opportunistic Intracellular Microorganisms
por: Wipasa, Jiraprapa, et al.
Publicado: (2014)

Seroprevalence of antibodies to measles, mumps, and rubella, and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand
por: Chaiwarith, Romanee, et al.
Publicado: (2016)

2231. Long-Term Immunogenicity of Four Doses and Four Double Doses vs. Standard Doses of Hepatitis B Vaccination in HIV-Infected Adults: An Extension of a Randomized Controlled Trial
por: Chaiwarith, Romanee, et al.
Publicado: (2018)

Immunogenicity and safety of 4 vs. 3 standard doses of HBV vaccination in HIV-infected adults with isolated anti-HBc antibody
por: Laksananun, Nattinee, et al.
Publicado: (2019)

1614. Efficacy and Safety of Adjusted Renal Dosing of Tenofovir DF Versus Abacavir Switching in HIV Patients with Decreased Glomerular Filtration Rate After Receiving Tenofovir DF-Based Regimen
por: Yamasmith, Eakkawit, et al.
Publicado: (2023)

Streptococcus agalactiae in adults at chiang mai university hospital: a retrospective study
por: Chaiwarith, Romanee, et al.
Publicado: (2011)

Hepatitis B Vaccination Induced TNF-α- and IL-2-Producing T Cell Responses in HIV− Healthy Individuals Higher than in HIV+ Individuals Who Received the Same Vaccination Regimen
por: Chawansuntati, Kriangkrai, et al.
Publicado: (2018)

Higher rate of long-term serologic response of four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: 4-year follow-up of a randomised controlled trial
por: Chaiwarith, Romanee, et al.
Publicado: (2019)

365. Neurocognitive Function Change after Switching from Efavirenz to Rilpivirine in HIV-Infected Adults: A Randomized Control Trial
por: Kaewpoowat, Quanhathai, et al.
Publicado: (2019)

Safety and immunogenicity of a 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A Phase I study (V114-028)
por: Ishihara, Yasunori, et al.
Publicado: (2023)

HIV-1 Induces Cytotoxic T Lymphocytes in the Cervix of Infected Women
por: Musey, Luwy, et al.
Publicado: (1997)

The Effect of a Maturing Antiretroviral Program on Early Mortality for Patients with Advanced Immune-Suppression in Soweto, South Africa
por: Otwombe, Kennedy N., et al.
Publicado: (2013)

Immune Alterations in Patients with Anti-Interferon-γ Autoantibodies
por: Chruewkamlow, Nuttapol, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_e4kpq3b3gst74nih5fdcafg47m